Cargando…
Genomic Determinants of Homologous Recombination Deficiency across Human Cancers
SIMPLE SUMMARY: Tumors with homologous recombination deficiency (HRD) respond to Poly-ADP ribose polymerase inhibitor (PARPi) therapy in breast, ovarian, prostate, and pancreatic cancers. However, in addition to a handful of known pathogenic variants including those affecting BRCA1/2, it remains unc...
Autores principales: | Qing, Tao, Wang, Xinfeng, Jun, Tomi, Ding, Li, Pusztai, Lajos, Huang, Kuan-Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472123/ https://www.ncbi.nlm.nih.gov/pubmed/34572800 http://dx.doi.org/10.3390/cancers13184572 |
Ejemplares similares
-
Diverse immune response of DNA damage repair-deficient tumors
por: Qing, Tao, et al.
Publicado: (2021) -
Genomic and molecular landscape of homologous recombination deficiency across multiple cancer types
por: Shi, Zhiwen, et al.
Publicado: (2023) -
Determinants of Homologous Recombination Deficiency in Pancreatic Cancer
por: Wattenberg, Max M., et al.
Publicado: (2021) -
Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types
por: Takamatsu, Shiro, et al.
Publicado: (2021) -
Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types
por: Takamatsu, Shiro, et al.
Publicado: (2022)